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Primary signet-ring cell carcinoma of the urinary bladder
Signet-ring cell carcinoma of the urinary bladder is a rare tumour, accounting for approximately 0,24% of all bladder 
malignancies. In this study, the clinicopathological findings in 13 cases are described. This malignancy is far more 
common in men than in women (ratio 11:2). The distribution by age and clinical symptoms can not distinguish it from 
transitional cell carcinoma. The tumour behaves like other high grade malignancies, presenting frequently at an 
advanced stage, and having an unfavourable clinical outcome. No special therapy seems superior to another.
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Introduction
Adenocarcinomas of the urinary bladder comprise 0.5 
to 2 % of all epithelial bladder neoplasms1. Direct 
extension of adenocarcinoma from an adjacent organ 
such as the colon or prostate is much more common 
than primary adenocarcinoma of the urinary bladder. 
Primary urinary bladder adenocarcinomas may be 
subdivided into three categories according to their 
origin. They arise either from metaplastic urothelium 
(vesical), from a remnant of the allantoic duct (urachal), 
or are associated with extrophy. A still more unusual 
variant is an adenocarcinoma primarily composed of 
signet-ring cells. Since the first description in 19552 
about 68  cases have been described, mostly as case 
reports, or within larger series of bladder and urachal 
carcinomas3“18. These tumours generally present as 
high-grade, high-stage lesions that have a uniformly 
poor prognosis. Histopathologically, primary adenocar­
cinomas of the urinary bladder must be distinguished 
from infiltrating adenocarcinomas from adjacent sites, 
or from metastatic tumours from distant sites. This 
report documents the clinicopathological features of 13 
signet-ring cell carcinomas of urinary bladder origin.
Address for correspondence: Dr R.Torenbeek, Department of 
Pathology, Free University Hospital, De Boelelaan 1117, 1081 HV 
Amsterdam, The Netherlands.
Materials and methods
Tumour specimens of 4191 consecutive patients with a 
primary urinary bladder malignancy were reviewed 
from the flies of the Departments of Pathology of the Free 
University Amsterdam, the Antoni van Leeuwenhoek 
Hospital Amsterdam, Reinier de Graaf Hospital (SSDZ) 
Delft and the Regional Pathology Laboratory Twente in 
the Netherlands. All tumours initially diagnosed as 
signet-ring cell carcinoma of the urinary bladder were 
further investigated. Clinical data were obtained from 
the patient's files. Primaries from another site were 
excluded by extensive clinical investigations, including 
CT scan of abdomen and other imaging techniques of 
organs at risk (stomach, colon, breast) and by prostate 
biopsies, Cases where there was doubt about their origin 
from the bladder, with only incidental signet-ring cells, 
or patients who had received prior anti-cancer therapy 
were not included. Ten cases (0.26%) of signet-ring cell 
carcinoma with at least 15% signet-ring cells were 
found. In addition, three incidental cases sent to us for a 
second opinion were studied.
All tissue specimens were formalin fixed and paraffin 
embedded. In all cases immunohistochemistry was 
routinely performed19,20, using the avidin-biotin- 
peroxidase technique, employing commercially avail­
able antibodies to polykeratin, epithelial membrane 
antigen (EMA), carcinoembryonic antigen (CEA),
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Table 1. Clinical features in 13 patients with primary singet-ring cell carcinoma of the urinary bladder
Case Age/Sex
Symptoms
(duration)
Cystoscopic
morphology Stage Therapy Outcome*
1 82/M Frequency, 
retention 
(3 weeks)
Non-
exophytic,
oedema
T4 RTh DOD 11
2 75/M Haematuria, 
frequency 
(3 days)
Superficial
tumour,
central
necrosis
T2 RTh,
intravesical
radium
ANED 8 7
3 78/M Frequency 
(11 months)
Oedema T 2 RTh DOD 15
4 79/M Haematuria 
(3 weeks)
Polypous,
massive
T3 RTh DOD 12
5 78/ F Haematuria 
(12 weeks)
Exophytic T4 RTh DOD 16
6 74/M Haematuria
(5 days)
Massive,
spheric
T4 Partial
cystectomy,
intravesical
caesium
DOD 48
7 51/M Frequency 
(2 weeks)
Hyperaemia,
oedema
T3 RTh ANED 6 7
8 44/M Haematuria 
(2 weeks)
Polypous T3 Total
cystectomy,
RTh
DOD 20
9 62/M Haematuria 
(2 days)
Focal granular T2 Total
cystectomy,
ANED 2 8
10 76/F Haematuria 
(6 weeks)
Exophytic T3 RTh DOD 3 6
11 83/M Frequen cy, 
incontinence 
(7 months)
Exophytic T3 None DOD 9
12 59/M Haematuria 
retention, 
flank pain 
(8 weeks)
Cobble­
stone,
Oedema
T2 Total
cystectomy,
RTh
DOD 24
13 71/M Dysuria 
frequency 
(8 weeks)
Large tumour, 
rigid wall
T4 None DOD 8
ANED, alive no evidence of disease; DOD, died of disease; M, male; F, female; RTh, radiation therapy. * Survival in months,
prostate specific antigen (PSA), OVTL 12/30 
(recognizing cytokeratin 7), and Ks20.8 (recognizing 
cytokeratin 20) (all Dakopatts, Denmark), 115D8 
(recognizing the MAM-6 epitope of the epithelial 
sialomucin. AvL; Amsterdam, the Netherlands), CAM 
5.2 (recognizing keratin 8 . Becton Dickinson; CA, USA). 
In addition, two antibodies recently developed in our
laboratory: E48 and U36 (recognizing two different 
epitopes present in squamous and transitional epithelia) 
were employed20,21. Four /¿m thick sections were cut 
and mounted on poly-L-lysine coated glass slides, 
deparafflnized, rehydrated, and treated with 0 .5% 
H2O2 in methanol to block endogenous peroxidase 
activity. For optimal staining results, sections to be
©  1996 Blackwell Science Ltd, HistopathnJogif, 28, 33-40.
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Table 2. Pathological features in 13 signet-ring ceil carcinomas of the urinary bladder
Case
Histological
type
% signet-ring 
cells
Additional
malignant
component
Status of 
adjacent 
urothelium
Epithelial
abnormalities
«
1 D 75 Dysplasia
2 D 30 tcc CIS
3 D 25 tcc CIS BN/CG
4 C 90 Normal
5 C 40 tcc
6 D 100 BN/SM
7 D 70 Normal
8 C 100 CC/CG
MM
9 D 75
10 D 80 CIS BN
11 D 15 S CUBIC CIS
12 D 60 tcc BN
13 D 60 Dysplasia
SRCC, signet-ring cell carcinoma; D, diffuse growth; C, colloid growth; tcc, transitional cell carcinoma; SCUB1C, small cell 
undifferentiated bladder carcinoma; CIS, carcinoma in situ; BN, von Brunn's nests; CG, cystitis glandularis; CC, cystitis cystica; 
SM, squamous metaplasia; MM, mucinous metaplasia.
labelled with anti-cytokeratins and CAM 5.2 were first 
digested with 0.5% trypsin, and sections to be labelled 
with E48 and U36 were first digested with 0.5% pepsin, 
in phosphate buffered saline (pH 7.4) for 20min at room 
temperature. These steps were not employed for other 
immunostains. Primary antibodies were then applied for 
1 h at room temperature in moisture chambers, followed 
by incubation (for 60 min) with a bio tin-labelled second 
layer horse-anti-mouse antibody (Vector Laboratories). 
After the latter, the avidin-biotin-per oxidase complex 
was added. Sections were developed with diaminobenzi- 
dine for 3 min, counterstained with hematoxylin, and 
mounted with depex. Appropriate positive and negative 
controls were used throughout. The neuroendocrine 
character of a component of small cell undifferentiated 
carcinoma present in one tumour was incubated with 
antibodies to neuron specific enolase (NSE), chromo- 
granin, synaptophysin and Leu 7, and subsequently 
stained by the same method.
Results
CLINICAL FINDINGS
The clinical findings are summarized in Table 1. Eleven 
patients were male and two were female. Their age
ranged from 44 to 83 years (mean 70.2 years). Gross 
haematuria was the commonest clinical presentation 
(eight patients), with duration of 2 days to 11 months. 
Four patients mainly complained of frequency, and two 
patients complained of pain. Mucinuria was not 
mentioned by any of the patients and none had a 
history of extrophy.
Transurethral resected specimens were available for 
nine patients, and partial cystectomy specimens for 
four. The primary tumour occurred at any site of the 
bladder mucosa, with a slight predeliction for the lateral 
walls. None of them fulfilled the criteria of urachal 
carcinoma. At cystoscopy, the tumours presented as 
circumscribed, solid lesions of 0.5-10 cm diameter 
(mean: 4.0cm) in seven patients (53.8%). Less than 
half of patients presented with a non-circumscribed 
tumour, diffusely infiltrating the bladder wail. Two of 
these patients had complaints of frequency and small 
voidings. All patients presented with advanced tumour 
stage with tumour invasion into the inner half of the 
muscular wall (stage T2; four cases), deep muscle or 
perivesical fat (stage T3; five cases), or beyond the 
bladder wall into the adjacent organs (stage T4; four 
cases).
Metastatic disease was evident in nine patients. 
Regional lymph node metastases were mostly present 
(six cases). Hematogeneous metastases occurred in the
©  1996 Blackwell Science Ltd, Histopathology, 28, 33-40.
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Figure 1. Colloid type of signet-ring cell carcinoma, with individual 
tumour cells floating in pools of mucin.
Figure 2. Intestinal metaplasia of the urothelium.
vertebral column arid ribs in three patients, skin and 
thoracic cavity both in one patient.
Therapy varied depending upon TNM-classification 
and general health of the patient. Four patients under­
went a cystectomy, together with radiation therapy in 
three. Seven patients received radiation therapy after 
transurethral resection of their tumour. In two patients, 
the treatment was limited to transurethral resection.
The long term clinical outcome was poor, Ten 
patients died of their disease between 8 and 48 
months after jthe diagnosis was made (mean: 2 0  
months, median 15 months). None of these patients 
was examined post-mortem. Three patients were free of 
disease at 28, 67 and 87 months of follow-up.
HISTOPATHOLOGY
The findings are summarized in Table 2. All tumours 
were considered as non-urachal. Transurethral resected 
specimens were received from nine patients, and the 
cystectomy specimens of four. Ten tumours were 
composed of signet-ring cells diffusely infiltrating the
bladder wall in a linitis plastica fashion. Three tumours 
showed a mixed pattern with obvious pools of mucin, 
with individual floating tumour cells (colloid type, 
Figure 1). The estimated percentage signet-ring cells 
varied from less than 50% in four cases, 50% to 7 5% in 
three cases to more than 75% in six cases.
Urothelium was present in the biopsies of 11 patients. 
Foci of cystitis cystica and cystitis glandularis were 
present in one and three cases, respectively; von 
Brunns’ nests were present in three cases. Atypical/ 
dysplastic urothelium was present in three cases, 
squamous and intestinal metaplasia were both seen in 
one case (Figure 2), Additional (pre)malignant compo­
nents were carcinoma in situ in four cases (Figure 3), 
transitional cell carcinoma in three cases. In one 
tumour, the signet-ring cell component merged into 
undifferentiated small cell carcinoma, with diffusely 
scattered isolated signet ring cells (Figure 4).
The immunohistochemical staining results are sum­
marized in Table 3. The signet-ring cell component 
showed positive immunoreactivity with polycytokeratin 
in all cases. The other epithelial markers (OVTL 12/30, 
Cam 5.2, keratin 20, EMA, 115D8, CEA) were positive
©  1996 Blackwell Science Ltd, Histapathology, 28, 33-40.
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Figure 3. Carcinoma in situ of the surface urothelium.
in nearly all cases. Staining for PSA as well as with E48 
and U36 was negative in all cases.
Discussion
Primary signet-ring cell carcinoma of the urinary 
bladder proper is an extremely rare tumour, accounting 
for 0.24% of all bladder malignancies in this study (10 
of 4191 patients). The usual clinical presentation of 
patients with primary signet-ring cell carcinoma of the 
urinary bladder does not differ from patients with other 
bladder malignancies15,22. Mean duration of the
Figure 4. Small cell undifferentiated carcinoma with diffusely scat­
tered isolated signet-ring cells (inset derived from another part of 
this tumour).
One of the main problems in signet-ring cell 
carcinoma of the urinary bladder is the exclusion of a 
small metastasizing primary tumour at another site,
symptoms is 2 months (3 days to 11 months) and and, therefore, the presence of a predominantly signet-
haematuria was the principal sign for which medical 
attention was sought. Most patients were in their 
seventh or eighth decade, and there was a strong male 
predominance (ratio 11:2). Mucinuria has been 
reported in 3% to 12% of the patients23,24, but was
ring cell component should prompt a thorough search 
for a primary carcinoma elsewhere27. In deciding 
whether the tumour is primary in the bladder or not, 
the presence of other elements (small cell carcinoma, 
transitional cell carcinoma) or the state of the
not mentioned by any of our patients. Signet-ring cell urothelium (carcinoma in situ) would favour the 
carcinomas of the urinary bladder generally follow a diagnosis of a primary rather than a secondary in the
bladder. As a rule, patients with primary adenocar-very aggressive course6,2 5, although, occasional long-
15term survival is reported . In this study, 77% of all cinoma of the bladder present initially with symptoms 
patients died of the disease, with a mean period of related to the bladder, while patients with bladder
survival of 2 0  months, independent of their stage at 
presentation. Two patients in this series are free of
involvement by metastases are more prone to present 
with extra vesical symptoms28. The presence of gland- 
disease, more than 4 years after radiation therapy. Two- ular metaplasia simulating intestinal mucosa has been 
and 5-year survival figures for patients with signet-ring associated with a significant risk of malignancy and,
cell carcinoma are 46% and 23%, respectively, which is 
statistically comparable to transitional cell carcinoma 
grade 326.
previously, primary adenocarcinomas were thought to 
arise from glandular metaplasia . However, cystitis 
glandularis is a recognized response to urinary tract
(C) 19lJ6 Blackwell Science Ltd, Histopntlwiogij, 28, 33-40,
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Table 3. Selected imunohistochemical findings In the signet-ring cell carcinoma component
Case
no. Ker Cam5.2 EMA CEA PSA 115D8 S-100 E48
1 + + + ( + ) _ + — —
2 H- + - nd — + =— —
3 + + + + f( + > —
— —
4 + + + + — + — —
5 + (+) + P + — +
— —
6 nd r+ — + — — — —
7 + — + + P + — + — —
8 f+ «+ ) H—h ( + ) — p + — —
9 + + + + — + — —
10 + (+) H—h P + — — —
11 + + Hr — — — —
12 + + + — — + — —
13 f+ — — + ““
Ker, Keratin; EMA, epithelial membrane antigen; CEA, carcinoembryonic antigen; PSA, prostate specific antibody; + + , strong 
positive; + , positive; (+ ), weak positive; pt partial (< 50%) positive; f, focal (< 10%) positive; nd, not done.
irritation and occurs in as many as 60% of asympto- 
matic bladders examined at autopsy , and a relation­
ship between cystitis glandularis and adenocarcinoma 
is no longer accepted31.
Distinction between primary bladder adeno­
carcinoma and urachal adenocarcinoma is important- 
in deciding on the optimal form of treatment. Primary 
biadder adenocarcinomas merit radical total cystect­
omy, as compared with partial cystectomy for urachal 
carcinomas. Urachal carcinoma is defined as a malig­
nant epithelial tumour situated in the dome or anterior 
wall of the urinary bladder, growing mostly intramural, 
with deep ramifications in the bladder wall, that is 
shown not to be secondary carcinoma28. In male 
patients it is particularly important to eliminate the 
prostate as a primary source of adenocarcinoma that 
has involved the bladder wall diffusely . In this 
study, all carcinomas showed reactivity with nearly all 
epithelial markers, while PSA was consistently nega­
tive. Prostatic adenocarcinomas may contain signet- 
ring cells, but these are not mucin secreting, and are 
immunoreactive with prostate specific antibody in 
contrast to the signet-ring cell carcinoma of the 
bladder34”36. Unfortunately, the urothelial origin of 
signet-ring cell carcinoma can not positively be 
identified, since there are no monoclonal antibodies 
described that are selectively expressed by bladder 
adenocarcinoma, and E48, previously described on 
benign and malignant urothelium, does not react with 
mucinous epithelium37.
Diseases that may simulate signet-ring cell carcinoma 
in the urinary bladder are nephrogenic adenoma 
(especially when tiny tubules are lined by a single cell
3 8
layer, containing mucin and a compressed nucleus ), 
lymphoma (with signet-ring appearance, due to nuclear 
distortion by intracytoplasmic accumulation of immu­
noglobulins39,40), and carcinoid (which may take on a 
signet-ring cell appearance, as is described in the gall 
bladder41). Furthermore, signet-ring cell carcinoma can 
be mimicked by degenerated lymphocytes with signet 
ring appearance which is an artefact induced by the 
TUR procedure42, in these cases immunohistochemistry 
may be helpful, using leucocyte common antigen or 
prostate specific antigen (in case of lymphoma or 
prostatic carcinoma) or neuroendocrine markers (in 
case of carcinoid).
The histogenesis of signet-ring cell carcinoma of the 
urinary bladder is thought to be either from the 
remnants of the cloaca or the totipotential transitional 
cell epithelium of the bladder43. Neoplastic transforma­
tion of urothelium may result in adenocarcinoma, If 
abundant mucin accumulates within the cytoplasm, 
the nucleus will become compressed giving it the 
characteristic signet-ring cell appearance. Rupture of 
either the mucin-distended glands or individual cells 
produces pools of mucin so characteristically observed 
in these neoplasms. The co-existence of epithelial 
abnormalities, such as von Brunns’ nests, cystitis 
cystica, cystitis glandularis, squamous and mucinous 
metaplasia, or additional malignant components such
©  1996 Blackwell Science Ltd, Histopathology; 28,"33-40.
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as transitional cell carcinoma and small cell undiffer­
entiated carcinoma, as was observed in 10 of our cases 
and reported in the literature, supports the latter 
hypothesis6,43.
With respect to the management of signet-ring cell 
carcinoma of the urinary bladder, review of the 
literature does not yield convincing information about 
the efficacy of the various therapeutic modalities16. In 
most cases, primary urinary bladder signet-ring cell 
carcinoma exhibit a diffusely infiltrative growth pat­
tern, and for this reason segmental resection would 
appear rarely feasible and generally unwise. Radical 
cystectomy seems the best that can be offered, but 
outcome in this and other series remains rather 
disappointing6,9. Signet-ring cell carcinomas are 
thought to be relatively radioresistant. In two cases 
described in the literature, the signet-ring cells pre­
dominate after radiotherapy, while the initial biopsies 
revealed predominantly transitional cell carcinoma. 
Chemotherapy has not been shown to be effective in 
the control of this disease 5.
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